Granules India growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+19.7%+5.9%
EBITDA+25.4%+9.1%
Net Income+18.7%+4.8%
EPS (adj.)+18.7%+4.8%
Total Assets+23.5%+16.3%
Total Equity+36.9%+21.5%
Free Cash Flow−20.3%−10.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GRANULES₹840.45

Granules India Ltd.

· Pharma & Health
₹ CrorePeersAUROPHARMAIPCALABAARTIDRUGSERISINDGNEMCUREJUBLPHARMACONCORDBIOMcap ₹20,826 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+19.7+5.9
EBITDA+25.4+9.1
Net Income+18.7+4.8
EPS (adj.)+18.7+4.8
Total Assets+23.5+16.3
Total Equity+36.9+21.5
Free Cash Flow-20.3-10.5
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.